| Typical Time-in-Range Improvement | +10β15 percentage points vs. MDI |
| A1C Reduction | 0.5β1.5% |
| CGM Update Frequency | Every 1β5 minutes |
| Target MARD for Safe Dosing | < 9% |
| Approved Age Range (Omnipod 5) | 2 years and older |
| Algorithm Response Time | 5-minute dosing cycles (780G) |
Key Takeaways
- Closed loop systems combine a CGM sensor, insulin pump, and control algorithm to automate insulin delivery
- Hybrid closed loop is the current standard; fully closed loop systems are emerging in 2025β2026
- Clinical trials show A1C reductions of 0.5β1.5% and up to 3 hours more time-in-range daily
- Compatible CGM sensors are critical β sensor accuracy directly determines dosing safety
- MDS Diabetes supplies leading CGM sensors compatible with major closed loop platforms
What Is a Closed Loop Insulin System?
A closed loop insulin system β often called an artificial pancreas β automatically adjusts insulin delivery based on real-time continuous glucose monitor (CGM) readings. A control algorithm processes sensor data and commands an insulin pump to increase, decrease, or suspend delivery without manual input.
System Components
- CGM Sensor: Measures interstitial glucose every 1β5 minutes
- Control Algorithm: Software (on a pump, phone, or dedicated device) that calculates insulin doses
- Insulin Pump: Delivers rapid-acting insulin subcutaneously
- Communication Link: Bluetooth or proprietary wireless protocol
Hybrid vs. Fully Closed Loop
| Feature | Hybrid Closed Loop | Fully Closed Loop |
|---|---|---|
| Meal announcements | Required | Not required |
| User interaction | Moderate | Minimal |
| Regulatory status (2026) | FDA approved | Clinical trials / limited approval |
| Example systems | Omnipod 5, MiniMed 780G, Tandem Control-IQ | iLet Bionic Pancreas |
Leading Systems in 2026
Omnipod 5 (Insulet)
Tubeless, phone-controlled system compatible with the Dexcom G6/G7. Targets a user-adjustable glucose goal of 110β150 mg/dL. Ideal for active users and children.
MiniMed 780G (Medtronic)
Uses Guardian 4 sensor with auto-correction boluses every 5 minutes. Achieves an average 76% time-in-range in real-world studies. Compatible with Medtronic's own sensor ecosystem.
Tandem Control-IQ+
Pairs with Dexcom G7. Features sleep and exercise activity modes. Updatable via software β a major long-term value advantage.
iLet Bionic Pancreas (Beta Bionics)
The most autonomous system available. Requires only body weight at setup; no carb counting needed. Uses Dexcom G6 sensor.
CGM Sensor Accuracy: The Critical Factor
Every closed loop decision depends on sensor accuracy. Mean Absolute Relative Difference (MARD) below 9% is considered clinically safe for automated dosing. The Dexcom G7 achieves 8.2% MARD; the FreeStyle Libre 3 achieves 7.8% MARD. Sensors must be worn correctly, calibrated per manufacturer guidelines, and replaced on schedule to maintain system safety.
MDS Diabetes stocks Dexcom G6, Dexcom G7, and FreeStyle Libre 3 sensors β the three CGM platforms most widely compatible with approved closed loop systems in 2026. Explore compatible sensors at mdsdiabetes.com to ensure your system performs at its best.
Who Benefits Most?
- Type 1 diabetes patients with variable glucose patterns
- Individuals with hypoglycemia unawareness
- Children and adolescents (Omnipod 5 approved age 2+)
- Adults with Type 2 diabetes on intensive insulin therapy (emerging evidence)
Actionable Setup Tips
- Rotate sensor insertion sites to maintain accuracy over time
- Set personalized glucose targets in collaboration with your endocrinologist
- Use activity modes before exercise to prevent post-workout hypoglycemia
- Download pump and CGM data monthly to review time-in-range trends